Vir Biotechnology, Inc. (VIR)

Vir Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	168.35	241.58	848.63	347.82	436.58	109.34
Short-Term Investments	746.12	1,281	1,553	360.33	300.29	274.1
Cash & Short-Term Investments	914.47	1,522	2,402	708.15	736.86	383.44
Cash Growth	-46.10%	-36.62%	239.20%	-3.90%	92.17%	289.50%
Accounts Receivable	-	-	-	773.08	-	-
Other Receivables	5.3	11.6	28.9	-	1.9	-
Receivables	5.3	11.6	28.9	773.08	1.9	-
Prepaid Expenses	37.79	40.95	57.84	73	25.61	13.38
Restricted Cash	89.6	13.27	12.68	8.59	7.99	6.18
Other Current Assets	-	-	17.62	-	-	-
Total Current Assets	1,047	1,588	2,519	1,563	772.37	403
Property, Plant & Equipment	125.57	167.2	188.17	130.05	79.89	16.31
Long-Term Investments	271.5	105.28	23.93	201.39	-	30.89
Goodwill	16.94	16.94	16.94	16.94	16.94	16.94
Other Intangible Assets	19.26	22.57	32.76	33.29	33.82	35.69
Other Long-Term Assets	17.94	18.86	21.23	9.78	15.75	9.25
Total Assets	1,498	1,919	2,802	1,954	918.76	512.07
Accounts Payable	7.31	6.33	6.42	6.52	5.08	5.88
Accrued Expenses	65.53	82	462.07	129.54	69.84	24.73
Current Portion of Leases	19.41	12.87	4.14	3.93	3.63	0.24
Current Income Taxes Payable	-	0.15	15.23	6.22	-	-
Current Unearned Revenue	15.2	64.85	15.52	98.21	6.45	6.18
Other Current Liabilities	9.72	9.2	7.65	96.83	14.07	22.18
Total Current Liabilities	117.16	175.41	511.03	341.24	99.06	59.21
Long-Term Leases	93.41	111.67	123.84	133.56	66.56	-
Long-Term Unearned Revenue	-	1.53	53.21	3.82	3.82	12.67
Long-Term Deferred Tax Liabilities	-	-	-	18.44	3.25	3.31
Other Long-Term Liabilities	47.06	40.22	36.05	25.36	29.22	12.95
Total Liabilities	257.63	328.82	724.13	522.42	201.91	88.13
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,895	1,829	1,710	1,572	1,385	793.05
Retained Earnings	-655.2	-237.82	377.24	-138.6	-667.18	-368.52
Comprehensive Income & Other	1.13	-0.82	-9.12	-1.1	-1.28	-0.6
Total Common Equity	1,241	1,590	2,078	1,432	716.85	423.94
Shareholders' Equity	1,241	1,590	2,078	1,432	716.85	423.94
Total Liabilities & Equity	1,498	1,919	2,802	1,954	918.76	512.07
Total Debt	112.81	124.54	127.97	137.49	70.18	0.24
Net Cash (Debt)	801.66	1,398	2,274	570.66	666.68	383.2
Net Cash Growth	-48.90%	-38.53%	298.50%	-14.40%	73.98%	333.96%
Net Cash Per Share	5.91	10.42	16.87	4.28	5.59	12.63
Filing Date Shares Outstanding	137.72	135.03	133.53	132.3	127.84	109.8
Total Common Shares Outstanding	136.71	134.78	133.24	131.16	127.42	107.65
Working Capital	930	1,413	2,008	1,222	673.3	343.79
Book Value Per Share	9.08	11.80	15.60	10.92	5.63	3.94
Tangible Book Value	1,205	1,551	2,028	1,382	666.1	371.31
Tangible Book Value Per Share	8.81	11.51	15.22	10.53	5.23	3.45
Machinery	46.13	49.4	41.93	22.57	18.77	13.88
Construction In Progress	0.71	0.23	-	26.93	1.14	0.14
Leasehold Improvements	53.14	80.29	84.42	7.83	7.27	7.12

Source: S&P Capital IQ. Standard template. Financial Sources.